The third test, EndoPredict (Myriad Genetics, Salt Lake City, UT), is a 11-gene RT-PCR test that provides prognostic information regarding the risk of distant recurrence of breast cancer to patients with HR+ and HER2- tumors [17]. The gene discussed is ERBB2; the disease is breast cancer.